IGM Biosciences Inc
NASDAQ:IGMS

Watchlist Manager
IGM Biosciences Inc Logo
IGM Biosciences Inc
NASDAQ:IGMS
Watchlist
Price: 1.27 USD -2.31% Market Closed
Market Cap: 76.6m USD

IGM Biosciences Inc
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

IGM Biosciences Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
IGM Biosciences Inc
NASDAQ:IGMS
Operating Expenses
-$133.8m
CAGR 3-Years
13%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$22.7B
CAGR 3-Years
-2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$11.6B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$13.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$5.6B
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$8.4B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-14%
No Stocks Found

IGM Biosciences Inc
Glance View

Market Cap
76.2m USD
Industry
Biotechnology

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGMS Intrinsic Value
2.21 USD
Undervaluation 43%
Intrinsic Value
Price

See Also

What is IGM Biosciences Inc's Operating Expenses?
Operating Expenses
-133.8m USD

Based on the financial report for Jun 30, 2025, IGM Biosciences Inc's Operating Expenses amounts to -133.8m USD.

What is IGM Biosciences Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-16%

Over the last year, the Operating Expenses growth was 44%. The average annual Operating Expenses growth rates for IGM Biosciences Inc have been 13% over the past three years , -16% over the past five years .

Back to Top